If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 2 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Cost-Benefit Analysis Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2019

Tumor Burden
Lung Neoplasms
Costs and Cost Analysis
Information Services
Feasibility Studies
Non-Small Cell Lung Carcinoma
Mutation
Research

BMS CA209-8D9 Analytics

Stenehjem, D. D.

University of Utah

8/1/187/31/19

Project: Research project

Drug Delivery Systems
Breast Neoplasms
Therapeutics
Systematic review

Research Output 2009 2019

Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center

Willis, C., Menon, J., Unni, S., Au, T., Yoo, M., Biskupiak, J., Brixner, D., Ndife, B., Joseph, G., Bonifacio, G., Stein, E., Tantravahi, S., Shami, P. J., Kovacsovics, T. & Stenehjem, D., Dec 2019, In : Leukemia research. 87, 106262.

Research output: Contribution to journalArticle

4'-N-benzoylstaurosporine
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Economics
Neoplasms

Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports

Gilreath, J. A., Wei, M., Paul, S., Parker, C. J., Stenehjem, D. D. & Rodgers, G. M., Apr 1 2019, In : Journal of Oncology Pharmacy Practice. 25, 3, p. 719-723 5 p.

Research output: Contribution to journalArticle

Purpura
Idiopathic Thrombocytopenic Purpura
Platelet Count
Thrombopoietin Receptors
Patient Harm
1 Citation (Scopus)

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time

Hahn, A. W., Stenehjem, D. D., Nussenzveig, R., Carroll, E., Bailey, E., Batten, J., Maughan, B. L. & Agarwal, N., Jan 1 2019, In : Cancer Treatment and Research Communications. 19, 100120.

Research output: Contribution to journalArticle

Prostatic Neoplasms
DNA
Neoplasms
Therapeutics
Biopsy
1 Citation (Scopus)

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center

Stenehjem, D. D., Au, T. H., Ngorsuraches, S., Ma, J., Bauer, H., Wanishayakorn, T., Nelson, R. S., Pfeiffer, C. M., Schwartz, J., Korytowsky, B., Oderda, G. & Brixner, D. I., Dec 1 2019, In : Melanoma research. 29, 6, p. 626-634 9 p.

Research output: Contribution to journalArticle

Open Access
Patient Preference
Melanoma
Neoplasms
Immunotherapy
Therapeutics
1 Citation (Scopus)

Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer

Weldon Gilcrease, G., Stenehjem, D. D., Wade, M. L., Weis, J., McGregor, K., Whisenant, J., Boucher, K. M., Thorne, K., Orgain, N., Garrido-Laguna, I. & Sharma, S., Jun 15 2019, In : Investigational New Drugs. 37, 3, p. 482-489 8 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Maximum Tolerated Dose
Stomatitis
Hypokalemia
Therapeutics